HC Wainwright restated their buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in a research note released on Friday. They currently have a $9.00 price target on the biopharmaceutical company’s stock.
“Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ.”,” HC Wainwright’s analyst wrote.
Other analysts also recently issued reports about the company. Maxim Group reaffirmed a hold rating on shares of Keryx Biopharmaceuticals in a report on Friday. BidaskClub downgraded Keryx Biopharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, August 16th. Citigroup decreased their price target on Keryx Biopharmaceuticals from $4.75 to $4.00 and set a neutral rating for the company in a report on Thursday, August 9th. Finally, Zacks Investment Research raised Keryx Biopharmaceuticals from a sell rating to a hold rating in a report on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $6.25.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. The business had revenue of $28.04 million for the quarter, compared to analysts’ expectations of $29.56 million. Equities analysts anticipate that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Keryx Biopharmaceuticals by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,056,811 shares of the biopharmaceutical company’s stock valued at $3,974,000 after purchasing an additional 102,014 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Keryx Biopharmaceuticals by 18.9% in the 2nd quarter. Rice Hall James & Associates LLC now owns 2,278,007 shares of the biopharmaceutical company’s stock valued at $8,565,000 after purchasing an additional 361,533 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Keryx Biopharmaceuticals by 8.8% in the 2nd quarter. BlackRock Inc. now owns 6,613,445 shares of the biopharmaceutical company’s stock valued at $24,866,000 after purchasing an additional 534,831 shares during the last quarter. UBS Group AG lifted its holdings in shares of Keryx Biopharmaceuticals by 126.0% in the 1st quarter. UBS Group AG now owns 231,934 shares of the biopharmaceutical company’s stock valued at $949,000 after purchasing an additional 129,296 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at about $399,000. 59.41% of the stock is owned by institutional investors and hedge funds.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Featured Story: Buyback
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.